01
World-class scientific team with leading minds in neuroscience,clinical psychology, and drug development
02
Deep IP moat with new chemical entities (NCEs) and strong patent protection through 2049+
03
First-mover advantage scalable, short-acting psychedelic therapeutics designed for clinical use
04
Targeting multibillion-dollar mental health markets underserved by existing therapies
05
Targeting phase 1 Trials for PMDD and depression indications.